EML4 and non-small cell lung carcinoma: Treatment with Pfizer’s kinase inhibitor crizotinib (PF02341066) led to a dramatic clinical response in EML4-ALK-positive NSCLC patients [133, 134], as well as in one patient with an SLC34A2-ROS1-fusion-positive tumor [58].